Skip to main content
. 2017 May 26;8(42):71981–71995. doi: 10.18632/oncotarget.18234

Figure 4. EMC cell lines provide novel in vitro tools to test therapeutic drugs for CLL.

Figure 4

(A) Gating strategy for DNA content (Propidium Iodide) analysis of EMC6 cells after 24 h culture in the absence or presence of Ibrutinib. Numbers indicate proportions of cells in the respective gates. (B) Relative proportions of cycling (S/G2-M) and apoptotic (sub-G1) EMC6 cultured (n = 3, in duplicate) in the presence of either ibrutinib (5 nM), idelalisib (100 nM) or in combination. Graphs are presented as normalized mean ± SEM (Untreated EMC6 cells were set to 1). (C) In vitro adhesion to fibronectin. EMC6 cells were pretreated with ibrutinib (10 nM), idelalisib (100 nM) or a combination (n = 3, in triplicate). Graphs are presented as normalized mean ±SD (100%= vehicle-treated EMC6 cells). *P < 0.05, **P < 0.01 (paired one-sample T-test).